| Name | SC66 |
| Description | SC66 is a AKT inhibitor in HepG2, HA22T/VGH, and PLC/PRF/5 cells (IC50: about 0.75 μg/ml, at 72 h). |
| In vitro | HepG2, HA22T/VGH, and PLC/PRF/5 cells had similar IC50 values of approximately 0.85 and 0.75 μg/ml at 48 and 72 hours for SC66, respectively. The most resistant cell line was Huh7(IC50: 3.1/2.8 μg/ml, at 48/72 h), while the Hep3B cell line was found to be the most sensitive, (IC50: 0.75/0.5 μg/ml, at 48/72 h). SC66 reduced cell viability in a time- and dose-dependent manner inhibited colony formation and induced apoptosis in HCC cells. SC66 treatment led to a reduction in total and phospho-AKT levels. In addition, SC66 induces the production of reactive oxygen species (ROS) and DNA damage. SC66 significantly potentiates the effects of both conventional chemotherapeutic and targeted agents, doxorubicin and everolimus, respectively. [1] |
| In vivo | In xenograft models, SC66 can inhibit tumor growth of Hep3B cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | SC-66 | SC66 | SC 66 | Protein kinase B | PKB | Inhibitor | inhibit | Apoptosis | Akt |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Ethyl linoleate | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Glycometabolism Compound Library | Bioactive Compound Library | Antidepressant Compound Library | Kinase Inhibitor Library | Hematonosis Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |